News Image

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Provided By GlobeNewswire

Last update: Mar 3, 2025

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025

Read more at globenewswire.com

APOGEE THERAPEUTICS INC

NASDAQ:APGE (6/12/2025, 2:11:02 PM)

43.37

+0.93 (+2.19%)



Find more stocks in the Stock Screener

Follow ChartMill for more